Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study*
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study*
Authors
Keywords
-
Journal
HIV CLINICAL TRIALS
Volume 17, Issue 1, Pages 29-37
Publisher
Informa UK Limited
Online
2016-02-22
DOI
10.1080/15284336.2015.1115585
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Unknown
- (2018) JOURNAL OF MEDICAL VIROLOGY
- 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects
- (2015) Danielle P. Porter et al. HIV CLINICAL TRIALS
- HIV Drug Resistance Mutations in Proviral DNA from a Community Treatment Program
- (2015) Anne Derache et al. PLoS One
- Antiretroviral Treatment of Adult HIV Infection
- (2014) Huldrych F. Günthard et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'
- (2014) C. Amiel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine
- (2014) S. Gallien et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants
- (2013) Frank J. Palella et al. AIDS
- 96-week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials
- (2013) Laurence Rimsky et al. ANTIVIRAL THERAPY
- Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz
- (2013) A. M. Geretti et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- APOBEC3G-Induced Hypermutation of Human Immunodeficiency Virus Type-1 Is Typically a Discrete “All or Nothing” Phenomenon
- (2012) Andrew E. Armitage et al. PLoS Genetics
- Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia
- (2011) M. Wirden et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In-depth analysis of G-to-A hypermutation rate in HIV-1 env DNA induced by endogenous APOBEC3 proteins using massively parallel sequencing
- (2010) Stefanie A. Knoepfel et al. JOURNAL OF VIROLOGICAL METHODS
- The Importance of Testing Genotypic Resistance in Proviral DNA of Patients Fully Responding to Highly Active Antiretroviral Therapy
- (2009) Lucia Palmisano et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Analysis of the Percentage of Human Immunodeficiency Virus Type 1 Sequences That Are Hypermutated and Markers of Disease Progression in a Longitudinal Cohort, Including One Individual with a Partially Defective Vif
- (2009) A. Piantadosi et al. JOURNAL OF VIROLOGY
- Conserved Footprints of APOBEC3G on Hypermutated Human Immunodeficiency Virus Type 1 and Human Endogenous Retrovirus HERV-K(HML2) Sequences
- (2008) A. E. Armitage et al. JOURNAL OF VIROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started